# Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

> **NCT05613296** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 95 (actual)

## Conditions studied

- ITP - Immune Thrombocytopenia
- Chronic ITP
- Refractory ITP

## Interventions

- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT05613296
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-05
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05613296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05613296, "Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05613296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*